East Hanover, New Jersey, United States
with other locations globally
At Novartis, we are driven by a single mission: to discover new ways to improve and extend people’s lives. Through science-based innovation we address some of society’s most challenging healthcare issues. Working to discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
Novartis focuses on innovative patent-protected medicines, generics and eye care products – segments where we have global reach and strong relations with our customers. Research and development (R&D) sits at the core of our business and central to our strategy. Our global organizations for manufacturing, business services and other functions help increase efficiency and promote excellence.
Reimagine what you could do at Novartis.
183 articles with Novartis
New data from an ongoing late-stage study reinforced the safety and efficacy of Cosentyx (secukinumab) as a beneficial treatment for patients with psoriatic arthritis and ankylosing spondylitis.
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis, or VOC) vs placebo
Novartis announces FDA filing acceptance of siponimod (BAF312), the first and only oral drug shown to delay disability progression in typical SPMS patients
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS), a highly debilitating form of MS characterized by gradual, irreversible worsening of disability, largely independent of relapses
MerLion Regains North American Rights to XTOROTM FDA-Approved Antibiotic for Treatment of Ear Infections
MerLion Pharmaceuticals announced that Novartis has made a portfolio decision and terminated the license between Alcon (a subsidiary of Novartis) and MerLion executed in 2010 and returned all rights to MerLion. MerLion now owns all rights to XTORO™ globally.
Cardurion Pharmaceuticals, today announced that it has expanded its leadership team with the addition of chief operating officer, Rebecca V. Frey, Pharm.D.
Agreement accelerates Novartis’ ability to use data and digital to transform commercial models, ensuring more meaningful interactions with healthcare providers
Last year, Novartis’ multiple sclerosis drug Gilenya generated more than $3 billion in revenue, with a little more than half of that coming from sales in the United States. As the drug faces patent loss in the future, Novartis is fighting to preserve that revenue driver with multiple lawsuits.
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
Kisqali is now the only CDK4/6 inhibitor indicated in combination with an aromatase inhibitor as first-line treatment for pre-, peri- or postmenopausal women with HR+/HER2- advanced breast cancer in the US
Tmunity Therapeutics, Inc. today announced the appointment of Christina Coughlin, MD, PhD, as Chief Medical Officer and Executive Vice President.
Adlai Nortye Biopharma Co., Ltd. ("Adlai Nortye" or "the Company"), a biopharmaceutical company dedicated to discovering and commercializing new drugs in the field of oncology/immuno-oncology, announced today that it has entered into a Global License Agreement ("the Agreement") with Novartis Pharma AG, a global pharmaceutical company.
Sandoz Inc. and its affiliate, Novartis Pharmaceuticals Corporation, voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance
Voluntary recall and notice of corrective action issued after discovering certain blister card packages distributed in the U.S. do not meet U.S. child-resistant packaging requirements
Cedilla Therapeutics Expands Leadership Team with New Appointments to Direct Biology, Drug Discovery and Proteomics
Cedilla Therapeutics today formally announced the appointment of three vice presidents with extensive experience in drug discovery to advance the company’s mission of harnessing existing protein stability mechanisms to redirect the course of disease.
Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis
Novartis announced today that the U.S. Food and Drug Administration (FDA) approved the inclusion of new evidence that Cosentyx® (secukinumab) significantly slows the progression of joint structural damage at Week 24 versus placebo in those with active psoriatic arthritis (PsA).1
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
Novartis announced 14-month results from the pivotal JULIET clinical trial showing ongoing durable responses are achievable with Kymriah® (tisagenlecleucel) when administered to adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%)
Spotlight on Biopharma Fellowships: AbbVie and Keck Graduate Institute Launch PharmD Fellowship P...
6/14/2018AbbVie and the Keck Graduate Institute (KGI) School of Pharmacy have partnered to form the first AbbVie-KGI Biopharmaceutical Industry Fellowship.
Now, two studies published in Nature Medicine suggest that CRISPR may lead to cancer unintentionally.
Aimmune Therapeutics, Inc. today announced the appointment of Jayson Dallas, M.D., as President and Chief Executive Officer.
Evolving Treatment Strategies in Multiple Myeloma: Janssen's Darzalex Leads a Host of Novel Agents in Redefining Treatment Strategies and Approaches
A new independent report from Spherix Global Insights examines the emerging trends and unveils near term shifts that are anticipated in this field which is experiencing its "golden age" of drug development.
One of the hot topics at this year’s BIO International Convention being held in Boston is “patient-centricity."